Prominent publications by Mario E Lacouture

KOL Index score: 17283

Importance: Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial.

Objectives: To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects.

Design, Setting, and Participants: Multicenter randomized clinical trial of women with breast cancer undergoing chemotherapy. Patients were enrolled from December ...

Known for Breast Cancer |  Scalp Cooling |  Clinical Trial |  Chemotherapy Alopecia |  Women Undergoing
KOL Index score: 17233

Importance: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy and safety of prolonged vemurafenib use in these patients are not defined. Here we analyze the final efficacy and safety data for vemurafenib in patients with ECD and LCH enrolled in the ...

Known for Chester Disease |  Vemurafenib Patients |  Ecd Lch |  Langerhans Cell |  Basket Study
KOL Index score: 15653

PURPOSE: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in the United States and Europe for the treatment of refractory metastatic colorectal cancer (mCRC). Skin toxicities are the most common adverse events with EGFR inhibitors. This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor.


Known for Skin Toxicities |  Quality Life |  Patients Reactive |  Emptive Treatment |  Study Incidence
KOL Index score: 14078

BACKGROUND: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported.


Known for Skin Toxicity |  Metastatic Colorectal Cancer |  Monoclonal Antibodies |  Safety Panitumumab |  Mcrc Patients
KOL Index score: 12588

Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF(V600E) mutations and respond to RAF inhibitors. However, detection of mutations in tissue biopsies is particularly challenging in histiocytoses due to low tumor content and stromal contamination. We applied a droplet-digital PCR assay for quantitative detection of the BRAF(V600E) mutation in plasma and urine cell-free (cf) DNA and performed a prospective, blinded study in 30 ...

Known for Brafv600e Mutation |  Lch Ecd |  Free Dna |  Histiocytic Disorders |  Response Therapy
KOL Index score: 12200

Background Regorafenib is a novel receptor tyrosine kinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced gastrointestinal stromal tumors (GISTs). The drug targets multiple receptors, including VEGF-R1/-R2/-R3, TIE-2, FGFR-1, PDGFR-α/β, KIT, RET, RAF, p38 MAPK. Adverse events include asthenia, hypertension, diarrhea, and hand-foot skin reaction (HFSR), with the latter representing one of the most clinically significant untoward events. The ...

Known for Hfsr Regorafenib |  Incidence Risk |  Foot Skin |  Mcrc Gist |  Kinase Inhibitor
KOL Index score: 11999

Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell carcinoma (BCC). Vismodegib, a first-in-class small-molecule inhibitor of hedgehog pathway signaling, is approved by regulatory authorities for the treatment of adults who have metastatic BCC or locally advanced BCC that has recurred after surgery, or who are not candidates for surgery and who are not candidates for radiation. A second inhibitor, sonidegib, was also recently approved for ...

Known for Hedgehog Pathway |  Basal Cell |  Weight Loss |  Muscle Spasms |  Candidates Surgery
KOL Index score: 11826

Hand-foot skin reaction (HFSR) is an emerging issue in cancer treatment with multitargeted tyrosine kinase inhibitors (TKIs), leading to morbidity, suboptimal dosing, and poor compliance. The overall risk of HFSR is not clear for sunitinib, a TKI effective for metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor. We therefore conducted a systematic review and a meta-analysis to determine the risk of developing HFSR with sunitinib. Databases from PubMed and Web of ...

Known for Renal Cell |  Hfsr Patients |  Foot Skin |  Multitargeted Kinase |  Eligible Studies
KOL Index score: 11514

BACKGROUND: Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. Despite no supportive evidence, various dosing schedules are used clinically to alleviate toxicities. This study evaluated the safety and activity of two regorafenib dosing schedules.

METHODS: In this randomised, multicentre, open-label, phase 2 study done in 39 outpatient cancer centres in the USA, ...

Known for Regorafenib Dose |  Colorectal Cancer |  Refractory Metastatic |  Primary Endpoint |  15 Patients
KOL Index score: 11451

PURPOSE: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of EGFR signaling occurs in colorectal tumor cells treated with RAF inhibitors and that the addition of an EGFR inhibitor enhances antitumor activity. These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.


Known for Egfr Inhibition |  Combined Braf |  Colorectal Cancer |  Mutant Metastatic |  Raf Inhibitors
KOL Index score: 11342

BACKGROUND: The anticancer multikinase inhibitors (MKIs) are associated with cutaneous adverse events, including hand-foot skin reaction (HFSR), a condition affecting 20%-40% of patients. Symptoms are usually mild, but can evolve into a painful condition that limits function and impacts quality of life (QoL), resulting in shortened cancer treatment duration or intensity. The goal of this study was to systematically review the literature on the prevention and palliation of MKI-associated ...

Known for Multikinase Inhibitors |  Foot Skin |  Mki Hfsr |  Hand Dermatoses |  Cutaneous Adverse Events
KOL Index score: 11070

Axitinib is a potent, selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We have performed a systematic analysis to investigate the risk of hand-foot skin reaction (HFSR) to axitinib and compare the differences in incidences between sorafenib, sunitinib, pazopanib and axitinib. Relevant studies were identified from PubMed (1998–2012). Eligible studies were limited to prospective Phase II-III clinical trials in which cancer patients were treated with axitinib ...

Known for Risk Hfsr |  Axitinib Sunitinib |  Foot Skin |  0001 Grade |  Relevant Studies
KOL Index score: 11066

Considering retreatment following recovery from an immune-related adverse event (irAE) is a common clinical scenario, but the safety and benefit of retreatment is unknown. We identified patients with advanced non-small cell lung cancer (NSCLC) treated with anti-PD-(L)1 who had treatment held due to irAEs and divided them into two groups: those retreated with anti-PD-(L)1 (retreatment cohort) or those who had treatment stopped (discontinuation cohort). Out of 482 NSCLC patients treated ...

Known for Retreatment Patients |  Humanized Antineoplastic Agents |  Monoclonal Antibodies |  Immunological Carcinoma |  Initial Irae
KOL Index score: 11007

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained ...

Known for Managing Toxicities |  Immune Checkpoint Inhibitors |  Immunotherapy Cancer |  Consensus Recommendations |  Topic Societies
KOL Index score: 10915

The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resistant EG cancer. We analyzed pretreatment tumor biopsies and, in select cases, performed comprehensive characterization of postmortem metastatic specimens following acquisition of drug ...

Known for Esophagogastric Cancer |  Tumor Drug Resistance |  Egfr Amplification |  Trastuzumab Afatinib |  Genomic Heterogeneity


Mario E Lacouture: Influence Statistics

Sample of concepts for which Mario E Lacouture is among the top experts in the world.
Concept World rank
interruption anticancer therapy #1
rash skin #1
oncodermatology clinics #1
induced dermatologic #1
skin clinical application #1
emergence supportive oncodermatology #1
dermatologic aes patients #1
factegfri18 english #1
nursing approach #1
incidence alopecia #1
impact daes #1
dermatologic infections #1
control dermatologic events #1
dedicated oncodermatologists #1
scalp hypothermia cia #1
rash 21 #1
“targeted” agents #1
purposerash #1
156 218 #1
ossified leiomyoma #1
accurate cataloging #1
adverse events ttfields #1
lapatinib lcap #1
effective therapy majority #1
reporting panitumumab #1
cia chemotherapy regimen #1
incidence rash #1
dermatologic toxic #1
cytotoxic chemotherapy cetuximab #1
life nails #1
hand–foot skin reaction #1
pria patients #1
nonagvhd rash #1
rash paronychia #1
spectrum ocular toxicities #1
spectrum target receptors #1
cabozantinib solid malignancies #1
patient costly #1
highgrade stomatitis #1
clinically toxicities #1
hfsr patients #1
cold caps #1
ebgm0052 #1
–foot skin reaction #1
specific diraes #1
bpm31543 #1
management skin rash #1
papulopustular eruption xerosis #1
photons chest wall #1
median cost patient #1

Key People For Breast Cancer

Top KOLs in the world
Ahmedin M Jemal
united states breast cancer addis ababa
Gabriel N Hortobagyi
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca L Siegel
united states colorectal cancer incidence rates
Charles M Perou
breast cancer gene expression intrinsic subtypes
Freddie Ian Bray
cancer incidence nordic countries mortality rates
Jacques Ferlay
cancer incidence global burden latin america

Mario E Lacouture:Expert Impact

Concepts for whichMario E Lacouturehas direct influence:Breast cancer,  Cutaneous metastases,  Dermatologic adverse events,  Egfr inhibitors,  Dermatologic toxicities,  Incidence risk,  Monoclonal antibodies.

Mario E Lacouture:KOL impact

Concepts related to the work of other authors for whichfor which Mario E Lacouture has influence:Immune checkpoint inhibitors,  Breast cancer,  Monoclonal antibodies,  Hepatocellular carcinoma,  Metastatic melanoma,  Skin toxicity,  Antineoplastic agents.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA;,, (A.M.K.);,, (M.E.L.) | Dermatology Service, Department of Medicine, Memorial Sloan Kettering C

FREE Custom List